Top

Published in:

01-05-2018 | Laboratory Investigation

C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin

Authors: Prit Benny Malgulwar, Aruna Nambirajan, Pankaj Pathak, Mohammed Faruq, Madhu Rajeshwari, Manmohan Singh, Vaishali Suri, Chitra Sarkar, Mehar Chand Sharma

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

Ependymomas (EPN) show site specific genetic alterations and a recent DNA methylation profiling study identified nine molecular subgroups. C11orf95-RELA and YAP1 fusions characterise the RELA and YAP1 molecular subgroups, respectively, of supratentorial (ST)-EPNs. Current guidelines recommend molecular subgrouping over histological grade for accurate prognostication. Clinicopathological features of ST-EPNs in correlation with C11orf95-RELA and YAP1 fusions have been assessed in only few studies. We aimed to study these fusions in EPNs, and identify diagnostic and prognostic markers. qRT-PCR and Sanger Sequencing for the detection of C11orf95-RELA, YAP1-MAMLD1 and YAP1-FAM118B fusion transcripts, gene expression analysis for NFKB1, and immunohistochemistry for p53, MIB-1, nestin, VEGF, and L1CAM were performed. 88 EPNs (10-Grade I and 78-Grade II/III) from all sites were included. RELA fusions were unique to Grade II/III ST-EPNs, detected in 81.4% (22/27) and 18.5% (5/27) of pediatric and adult ST-EPNs respectively. ST-EPNs harbouring RELA fusions showed frequent grade III histology (81.5%), clear cell morphology (70.3%), upregulated NFKB1 expression, MIB-1 labelling indices (LI) ≥ 10% (77.8%), and immunopositivity for nestin (95.7%), VEGF (72%), L1CAM (79%), and p53 (64%). Presence of RELA fusions, L1CAM immunopositivity and MIB-1 LI ≥ 10% associated with poor outcome. L1CAM showed 81% concordance with RELA fusions. YAP1-MAMLD1 fusion was identified in a single RELA fusion negative adult anaplastic ST-EPN. RELA fusions are frequent in ST-EPNs and associate with poor outcome. L1CAM is a surrogate immunohistochemical marker. RELA fusion positive ST-EPNs strongly express nestin indicating increased stemness. Further evaluation of the interactions between NFKB and stem cell pathways is warranted.

Available only for authorised users

Ellison DW, McLendon R, Wiestler OD et al (2016) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn, IARC, Lyon, pp 106–112

Ellison DW, Kocak M, Figarella-Branger D et al (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7CrossRefPubMedPubMedCentral

Zamecnik J, Snuderl M, Eckschlager T et al (2003) Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 16:980–991CrossRefPubMed

Dyer S, Prebble E, Davison V et al (2002) Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 161:2133–2141CrossRefPubMedPubMedCentral

Taylor MD, Poppleton H, Fuller C et al (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323–335CrossRefPubMed

Raghunathan A, Wani K, Armstrong TS et al (2013) Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol 23:584–594CrossRefPubMed

Pajtler KW, Witt H, Sill M et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743CrossRefPubMedPubMedCentral

Parker M, Mohankumar KM, Punchihewa C et al (2014) C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506:451–455CrossRefPubMedPubMedCentral

Pietsch T, Wohlers I, Goschzik T et al (2014) Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway. Acta Neuropathol 127:609–611CrossRefPubMed

10.

Figarella-Branger D, Lechapt-Zalcman E, Tabouret E et al (2016) Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro Oncol 18:919–927CrossRefPubMedPubMedCentral

11.

Wani K, Vera-Bolanos E, Armstrong T et al (2014) P04.01 RELA fusion defines clinicopathologic subsets of supratentorial ependymoma: a study from the collaborative ependymoma research network [abstract]. Neuro Oncol 16:ii36CrossRefPubMedCentral

12.

Cachia D, Wani K, Penas-Prado M et al (2015) C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. Brain Tumor Pathol 32:105–111CrossRefPubMed

13.

Pajtler KW, Mack SC, Ramaswamy V et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133:5–12CrossRefPubMed

14.

Rajeshwari M, Sharma MC, Kakkar A et al (2016) Evaluation of chromosome 1q gain in intracranial ependymomas. J Neurooncol 127:271–278CrossRefPubMed

15.

Sharma V, Purkait S, Takkar S et al (2016) Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors. Brain Tumor Pathol 33:117–128CrossRefPubMed

16.

Sharma MC, Ghara N, Jain D et al (2009) A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas. Neuropathology 29:148–155CrossRefPubMed

17.

Nambirajan A, Sharma MC, Gupta RK, Suri V, Singh M, Sarkar C (2014) Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas. Neuropathol Appl Neurobiol 40:714–725CrossRefPubMed

18.

Ebert C, von Haken M, Meyer-Puttlitz B et al (1999) Molecular genetic analysis of ependymal tumors.NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 155:627–632CrossRefPubMedPubMedCentral

19.

Witt H, Mack SC, Ryzhova M et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143–157CrossRefPubMedPubMedCentral

20.

Johnson RA, Wright KD, Poppleton H et al (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632–636CrossRefPubMedPubMedCentral

21.

Godfraind C (2009) Classification and controversies in pathology of ependymomas. Childs Nerv Syst 25:1185–1193CrossRefPubMed

22.

Xie TX, Xia Z, Zhang N, Gong W, Huang S (2010) Constitutive NF-kappa B activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol Rep 23:725–732CrossRefPubMed

23.

Nobusawa S, Hirato J, Sugai T et al (2016) Atypical teratoid/rhabdoid tumor(AT/RT) arising from ependymoma: a type of AT/RT secondarily developing from other primary central nervous system tumors. J Neuropathol Exp Neurol 75:167–174CrossRefPubMed

24.

Panagopoulos I, Micci F, Thorsen J et al (2013) Fusion of ZMYND8 and RELA genes in acute erythroid leukemia. PLoS ONE 8:e63663CrossRefPubMedPubMedCentral

25.

Okazaki T, Sakon S, Sasazuki T et al (2003) Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun 300:807–812CrossRefPubMed

26.

Hoesel B, Schmid JA (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12:86CrossRefPubMedPubMedCentral

27.

Milde T, Hielscher T, Witt H et al (2012) Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 22:848–860CrossRefPubMed

28.

Fan X, Matsui W, Khaki L et al (2006) Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66:7445–7452CrossRefPubMed

29.

Gupta RK, Sharma MC, Suri V, Kakkar A, Singh M, Sarkar C (2014) Study of chromosome 9q gain, Notch pathway regulators and Tenascin-C in ependymomas. J Neurooncol 116:267–274CrossRefPubMed

30.

Garner JM, Fan M, Yang CH et al (2013) Constitutive activation of signal transducer and activator of transcription 3(STAT3)and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 288:26167–26176CrossRefPubMedPubMedCentral

31.

Li Q, Ford MC, Lavik EB, Madri JA (2006) Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res 84:1656–1668CrossRefPubMed

32.

Thomasova D, Mulay SR, Bruns H, Anders HJ (2012) p53- independent roles of MDM2 in NF-kappaB signaling: implications for cancer therapy,wound healing, and autoimmune diseases. Neoplasia 14:1097–1101CrossRefPubMedPubMedCentral

33.

Tzaridis T, Milde T, Pajtler KW et al (2016) Low-dose actinomycin-D treatment re-establishes the tumour suppressive function of P53 in RELA-positive ependymoma. Oncotarget 7:61860–61873CrossRefPubMedPubMedCentral

34.

Kiefel H, Pfeifer M, Bondong S, Hazin J, Altevogt P (2011) Linking L1CAM-mediated signaling to NF-κB activation. Trends Mol Med 17:178–187CrossRefPubMed

35.

Wani K, Armstrong TS, Jones DT et al (2014) BI-30 characterization of L1CAM as a clinical marker for the C11orf95-RELA fusion in supratentorial ependymomas [Abstract]. Neuro Oncol 16(suppl_5):v30CrossRefPubMedCentral

Title: C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin
Authors: Prit Benny Malgulwar
Aruna Nambirajan
Pankaj Pathak
Mohammed Faruq
Madhu Rajeshwari
Manmohan Singh
Vaishali Suri
Chitra Sarkar
Mehar Chand Sharma
Publication date: 01-05-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2767-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Renin angiotensin system and its role in biomarkers and treatment in gliomas

Prediction of progression in skull base meningiomas: additional benefits of apparent diffusion coefficient value

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Clinical applicability of and changes in perfusion MR imaging in brain metastases after stereotactic radiotherapy

Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors

The predictive potential of hyponatremia for glioblastoma patient survival